Michael Metzger, Syndax Pharmaceuticals CEO
Syndax's Revuforj wins FDA approval in aggressive form of leukemia
Syndax Pharmaceuticals won the first FDA approval last week in a new class of medicines called menin inhibitors.
The treatment, Revuforj, will be available as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
